- Home
- DOCU vs UTHR Comparison
DOCU vs UTHR Comparison
Compare DOCU & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOCU
- UTHR
- Stock Information
- Founded
- DOCU 2003
- UTHR 1996
- Country
- DOCU United States
- UTHR United States
- Employees
- DOCU N/A
- UTHR N/A
- Industry
- DOCU EDP Services
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- DOCU Technology
- UTHR Health Care
- Exchange
- DOCU Nasdaq
- UTHR Nasdaq
- Market Cap
- DOCU 14.4B
- UTHR 15.5B
- IPO Year
- DOCU 2018
- UTHR 1999
- Fundamental
- Price
- DOCU $79.87
- UTHR $366.56
- Analyst Decision
- DOCU Hold
- UTHR Buy
- Analyst Count
- DOCU 15
- UTHR 14
- Target Price
- DOCU $63.00
- UTHR $370.86
- AVG Volume (30 Days)
- DOCU 2.1M
- UTHR 371.2K
- Earning Date
- DOCU 12-05-2024
- UTHR 10-30-2024
- Dividend Yield
- DOCU N/A
- UTHR N/A
- EPS Growth
- DOCU N/A
- UTHR 25.10
- EPS
- DOCU 4.72
- UTHR 22.72
- Revenue
- DOCU $2,858,474,000.00
- UTHR $2,756,200,000.00
- Revenue This Year
- DOCU $8.84
- UTHR $26.32
- Revenue Next Year
- DOCU $5.89
- UTHR $10.37
- P/E Ratio
- DOCU $16.68
- UTHR $16.00
- Revenue Growth
- DOCU 7.70
- UTHR 25.04
- 52 Week Low
- DOCU $42.12
- UTHR $208.62
- 52 Week High
- DOCU $83.68
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- DOCU 64.23
- UTHR 44.36
- Support Level
- DOCU $77.06
- UTHR $353.65
- Resistance Level
- DOCU $80.65
- UTHR $417.82
- Average True Range (ATR)
- DOCU 2.26
- UTHR 10.93
- MACD
- DOCU -0.21
- UTHR -4.26
- Stochastic Oscillator
- DOCU 67.01
- UTHR 16.30
About DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in May 2018.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.